These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 11434453)

  • 41. Protecting the vasculature: an eye toward the future.
    Nayler WG; Gu XH
    Am J Cardiol; 1990 Nov; 66(18):23H-27H. PubMed ID: 2147359
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [A comparison between amlodipine and nifedipine retard in patients with essential arterial hypertension].
    Terrachini V; Canale C; Lonati A; Masperone MA; Bruzzone F; Malvestiti FM; Caponnetto S
    Clin Ter; 1992 Apr; 140(4):383-9. PubMed ID: 1534044
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of barnidipine on blood pressure and serum metabolic parameters in patients with essential hypertension: a pilot study.
    Spirou A; Rizos E; Liberopoulos EN; Kolaitis N; Achimastos A; Tselepis AD; Elisaf M
    J Cardiovasc Pharmacol Ther; 2006 Dec; 11(4):256-61. PubMed ID: 17220472
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of the vasodilatory beta-blocker, nipradilol, and Ca-antagonist, barnidipine, on insulin sensitivity in patients with essential hypertension.
    Kosegawa I; Inaba M; Morita T; Awata T; Katayama S
    Clin Exp Hypertens; 1998 Oct; 20(7):751-61. PubMed ID: 9764719
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical pharmacokinetics of amlodipine.
    Meredith PA; Elliott HL
    Clin Pharmacokinet; 1992 Jan; 22(1):22-31. PubMed ID: 1532771
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [The pharmacokinetic and pharmacodynamic characteristics of foridon during interaction with the metabolic oxidation inhibitor dopegit].
    Kukes VG; Alekhin SN; Rumiantsev AS; Gneushev ET; Gushchin AS; Germanov DV
    Eksp Klin Farmakol; 1993; 56(5):38-41. PubMed ID: 8312808
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Acute and long-term effects of nitrendipine on resting and exercise hemodynamics in essential hypertension.
    Nannan ME; Melin JA; Vanbutsele RJ; Lavenne F; Detry JM
    J Cardiovasc Pharmacol; 1984; 6 Suppl 7():S1043-8. PubMed ID: 6085364
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Amlodipine: a once daily calcium antagonist.
    Burges RA
    J Hum Hypertens; 1991 Aug; 5 Suppl 1():49-54. PubMed ID: 1834846
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of antihypertensive treatment on circulating endothelial progenitor cells in patients with mild essential hypertension.
    de Ciuceis C; Pilu A; Rizzoni D; Porteri E; Muiesan ML; Salvetti M; Paini A; Belotti E; Zani F; Boari GE; Rosei CA; Rosei EA
    Blood Press; 2011 Apr; 20(2):77-83. PubMed ID: 21114380
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Felodipine/metoprolol: a review of the fixed dose controlled release formulation in the management of essential hypertension.
    Haria M; Plosker GL; Markham A
    Drugs; 2000 Jan; 59(1):141-57. PubMed ID: 10718104
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetics and pharmacodynamics of amlodipine.
    Abernethy DR
    Cardiology; 1992; 80 Suppl 1():31-6. PubMed ID: 1534713
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Amlodipine in hypertension: an overview of the clinical dossier.
    Julius S
    J Cardiovasc Pharmacol; 1988; 12 Suppl 7():S27-33. PubMed ID: 2467123
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative actions of dihydropyridine slow channel calcium blocking agents in conscious dogs: systemic and coronary hemodynamics with and without combined beta adrenergic blockade.
    Warltier DC; Zyvoloski MG; Gross GJ; Brooks HL
    J Pharmacol Exp Ther; 1984 Aug; 230(2):367-75. PubMed ID: 6146711
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fixed-dose combination enalapril/nitrendipine: a review of its use in mild-to-moderate hypertension.
    Siddiqui MA; Plosker GL
    Drugs; 2004; 64(10):1135-48. PubMed ID: 15139792
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dihydropyridine calcium antagonists and the trough: peak ratio: focus on adverse effects.
    Myers MG
    J Hypertens Suppl; 1994 Nov; 12(8):S73-6; discussion S76-7. PubMed ID: 7707160
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fixed combination trandolapril/verapamil sustained-release: a review of its use in essential hypertension.
    Muijsers RB; Curran MP; Perry CM
    Drugs; 2002; 62(17):2539-67. PubMed ID: 12421112
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Barnidipine real-life tolerability in arterial hypertension: results from the BASIC-HT study.
    Lins R; Marckx P; Vandebeek R; Vanhoutvinck C; Neuville O
    Acta Clin Belg; 2015 Aug; 70(4):244-50. PubMed ID: 25816195
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Plasma concentration-response relationships for some cardiovascular effects of dihydropyridines in healthy subjects.
    Graefe KH; Ziegler R; Wingender W; Rämsch KD; Schmitz H
    Clin Pharmacol Ther; 1988 Jan; 43(1):16-22. PubMed ID: 3335117
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacologic profile of amlodipine.
    Burges RA; Dodd MG; Gardiner DG
    Am J Cardiol; 1989 Nov; 64(17):10I-18I; discussion 18I-20I. PubMed ID: 2554708
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The pharmacological properties of lipophilic calcium antagonists.
    van Zwieten PA
    Blood Press Suppl; 1998; 2():5-9. PubMed ID: 9850436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.